This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gillespie, G. Y. Articles by Rosenfeld, S. S. Search for Related Content PubMed PubMed Citation Articles by Gillespie, G. Y. Articles by Rosenfeld, S. S.

Glioma Migration Can Be Blocked by Nontoxic Inhibitors of Myosin II¹

Division of Neurosurgery [G. Y. G.] and Departments of Neurobiology [L. S., T. M.], Neuropathology [C. L. G.], and Neurology [S. S. R.], University of Alabama at Birmingham, Birmingham, Alabama 35294

Anaplastic gliomas are infiltrative tumors, and their ability to migrate through normal brain contributes to their highly malignant behavior. Invasion of brain requires cell motility, which in turn depends on the activity of the cytoskeleton. A cytoskeletal component central to this process is myosin II, the cytoplasmic analogue of smooth and skeletal muscle myosin. Myosin II activity is regulated by the enzyme myosin light chain kinase, which activates myosin II by phosphorylating it on its regulatory light chain. We have investigated the role of myosin II in glioma motility and invasiveness by examining the effects of two inhibitors of myosin light chain kinase, ML7 and KT5926. Both drugs are potent inhibitors of both glioma motility, as measured by a scrape motility assay, and an in vitro haptotaxis assay. The inhibition of in vitro haptotaxis follows the dose-response relationship expected for competitive inhibition of myosin light chain kinase by these drugs and is seen at drug concentrations that are nontoxic. These results highlight the important role that myosin II contributes to glioma invasiveness and suggest that it may serve as a target in future strategies at blocking invasion by these tumors.

This article has been cited by other articles:

				M. Bazzaro, A. Santillan, Z. Lin, T. Tang, M. K. Lee, R. E. Bristow, I.-M. Shih, and R. B.S. Roden Myosin II Co-Chaperone General Cell UNC-45 Overexpression Is Associated with Ovarian Cancer, Rapid Proliferation, and Motility Am. J. Pathol., November 1, 2007; 171(5): 1640 - 1649. [Abstract] [Full Text] [PDF]

				M. E. Gonzalez, E. A. Peterson, L. M. Privette, J. L. Loffreda-Wren, L. M. Kalikin, and E. M. Petty High SEPT9_v1 Expression in Human Breast Cancer Cells Is Associated with Oncogenic Phenotypes Cancer Res., September 15, 2007; 67(18): 8554 - 8564. [Abstract] [Full Text] [PDF]

				S. S. Rosenfeld, J. Xing, L.-Q. Chen, and H. L. Sweeney Myosin IIB Is Unconventionally Conventional J. Biol. Chem., July 18, 2003; 278(30): 27449 - 27455. [Abstract] [Full Text] [PDF]

				M. A. Watson, A. Perry, V. Budhjara, C. Hicks, W. D. Shannon, and K. M. Rich Gene Expression Profiling with Oligonucleotide Microarrays Distinguishes World Health Organization Grade of Oligodendrogliomas Cancer Res., March 1, 2001; 61(5): 1825 - 1829. [Abstract] [Full Text]

				R. Eddy, L. Pierini, F Matsumura, and F. Maxfield Ca2+-dependent myosin II activation is required for uropod retraction during neutrophil migration J. Cell Sci., January 4, 2000; 113(7): 1287 - 1298. [Abstract] [PDF]